Vittoria Biotherapeutics specializes in developing next-generation T-cell therapies that revolutionize the field. Their Senza5 Technology enhances the effectiveness, safety, and versatility of cell-based treatments during preclinical stages. With a strong focus on expanding the applications of CAR-based therapeutics, the company utilizes innovative cell engineering and gene editing technologies. By addressing unmet medical needs, Vittoria Biotherapeutics is at the forefront of providing groundbreaking solutions in the field of gene-edited cell therapeutics.